Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
401 PROFESSIONAL DRIVE GAITHERSBURG, MD 20879 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 5,464 | 8,417 | |||
| Cash and cash equivalent | 2,576 | 8,417 | |||
| Short-term investments | 2,887 | ||||
| Receivables | 15 | ||||
| Prepaid expense | 114 | 161 | |||
| Total current assets: | 5,593 | 8,578 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 334 | 56 | |||
| Property, plant and equipment | 25 | 13 | |||
| Other undisclosed noncurrent assets | 6 | ||||
| Total noncurrent assets: | 359 | 75 | |||
| TOTAL ASSETS: | 5,952 | 8,654 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 117 | ||||
| Accounts payable | 117 | ||||
| Debt | 731 | ||||
| Due to related parties | ✕ | ✕ | 796 | ||
| Other undisclosed current liabilities | 311 | 63 | |||
| Total current liabilities: | 1,042 | 976 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 135 | ||||
| Long-term debt, excluding current maturities | 135 | ||||
| Liabilities, other than long-term debt | 304 | ||||
| Operating lease, liability | 304 | ||||
| Derivative instruments and hedges, liabilities | |||||
| Other undisclosed noncurrent liabilities | 415 | ||||
| Total noncurrent liabilities: | 854 | ||||
| Total liabilities: | 1,896 | 976 | |||
| Equity | |||||
| Equity, attributable to parent | 4,056 | 7,678 | |||
| Common stock | 0 | 0 | |||
| Additional paid in capital | 29,489 | 16,573 | |||
| Accumulated deficit | (25,433) | (8,895) | |||
| Total equity: | 4,056 | 7,678 | |||
| TOTAL LIABILITIES AND EQUITY: | 5,952 | 8,654 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Revenues (Sublease Income) | 8 | |||
| Gross profit: | 8 | |||
| Operating expenses | (5,892) | (2,554) | ||
| Other undisclosed operating loss | (8) | |||
| Operating loss: | (5,892) | (2,554) | ||
| Nonoperating expense | (700) | (474) | ||
| Interest and debt expense | (2,123) | 329 | ||
| Loss from continuing operations before equity method investments, income taxes: | (8,716) | (2,700) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 2,123 | (329) | ||
| Loss from continuing operations: | (6,593) | (3,028) | ||
| Other undisclosed net loss | ||||
| Net loss: | (6,593) | (3,028) | ||
| Other undisclosed net income attributable to parent | ||||
| Net loss attributable to parent: | (6,593) | (3,028) | ||
| Preferred stock dividends and other adjustments | (71) | |||
| Net loss available to common stockholders, diluted: | (6,593) | (3,099) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net loss: | (6,593) | (3,028) | ||
| Comprehensive loss, net of tax, attributable to parent: | (6,593) | (3,028) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.